Neuroprotective peptides as drug candidates against Alzheimer's disease

Journal of Applied Biomedicine

Volumn 3, Issue 2, 2005, Pages

  Patočka, Jiří ^a,b   Slaninová, Jiřina ^c   Kunešová, Gabriela ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Abeta peptide; Alzheimer's disease; Neuroprotective peptide

Indexed keywords

ACTIVITY DEPENDENT NEUROTROPHIC FACTOR; ACTIVITY DEPENDENT NEUROTROPHIC FACTOR 9; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOPTOSIS ANTAGONIZING TRANSCRIPTION FACTOR; ARGINYLGLUTAMYLARGININE; BETA SECRETASE; BETA SHEET BREAKER PEPTIDE; CHOLINESTERASE INHIBITOR; GALANIN; GAMMA SECRETASE; GLYCYLPROLYLARGININE; HUMANIN; INTERLEUKIN 11; INTERLEUKIN 6; LITHIUM SALT; MEMANTINE; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; NEUROPEPTIDE Y; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PEPTIDE; PROTEIN BCL W; SOMATOMEDIN C; SOMATOSTATIN; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALZHEIMER DISEASE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; SENILE PLAQUE; STRUCTURE ACTIVITY RELATION;

EID: 27444435757     PISSN: 1214021X     EISSN: 12140287     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Alcalay R.N., Giladi E., Pick C.G., Gozes I.: Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett. 361: 128-131, 2004.
2. Bassan M., Zamostiano R., Davidson A. et al.: Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72: 1283-1293, 1999.
3. Beni-Adani L., Gozes I., Cohen Y. et al.: A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injured mice. J. Pharmacol. Exp. Ther. 296: 57-63, 2000.
4. Blondel O., Collin C., McCarran B. et al.: A gliaderived signal regulating neuronal differentiation. J. Neurosci. 20: 8012-8020, 2000.
5. Brenneman D.E., Spong C.Y., Hauser J.M. et al.: Protective peptides that are orally active and mechanistically nonchiral. J.Pharm.Exp.Ther. 309: 1190-1197, 2004.
6. Brenneman D.E., Gozes I.: A femtomolar-acting neuroprotective peptide. J. Clin. Incest. 97: 2299-2307, 1996.
7. Brenneman D.E., Hauser J., Neale E. et al.: Activity-dependent neurotrophic factor: structure-activity relationships of femtomolaracting peptides. J. Pharmacol. Exp. Ther. 285: 619-627, 1998.
8. Chacon M.A., Barria M.I., Soto C., Inestrosa N.C.: Beta-sheet breaker peptide prevents Abetainduced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry. 9: 953-961, 2004.
9. Counts S.E., Perez S.E., Ginsberg S.D., DeLacalle S., Mufson E.J.: Galanin in Alzheimer disease. Mol. Interv. 3: 137-156, 2004.
10. Counts S.E., Perez S.E., Kahl U.: Galanin: neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. CNS Drug Rev. 7: 445-470, 2001.
11. Craft S., Asthana S., Newcomer J.W. et al.: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 56: 1135-1140, 1999.
12. Croom J., Taylor I.L.: Neuropeptide Y, peptide YY and aluminum in Alzheimer's disease: is there an etiological relationship? J. Inorg. Biochem. 87: 51-56, 2001.
13. Dejda A., Matczak I., Nosák J.Z.: Postepy. Hig. Med. Dosw. 58: 18-26, 2004.
14. Eldar-Finkelman H.: Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8: 126-132, 2002.
15. Fisher A., Hanin I.: Potential animal models for senile dementia of Alzheimer's type, with emphasis on AF64A-induced cholinotoxicity. Annu. Rev. Pharmacol. Toxicol. 26: 161-81, 1986.
16. Glazner G.W., Camandola S., M.P. Mattson M.P.: Nuclear factor kappa B mediates the cell survival-promoting action of activity dependent neurotrophic factor peptide-9. J. Neurochem. 75: 101-108, 2000.
17. Gotz J., Chen F., van Dorpe J., Nitsch R.M.: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495, 2001.
18. Gozes I., Spier A.S.: Peptides as drug targets to Alzheimer's disease: Drug Develop. Res. 56: 47581, 2002.
19. Gozes I.: Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci. 24: 700-705, 2001.
20. Gozes I., Brenneman D.E. : VIP molecular biology and neurobiological function. Mol. Neurobiol. 3: 201-236, 1989.
21. Gozes I., Giladi E., Pinhasov A., Bardea A., Brenneman D.E.: Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a watermaze. J. Pharmacol. Exp. Ther. 93: 1091-1098, 2000.
22. Gozes I., Divinsky I., Pilzer I. et al.: From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Mol. Neurosci 20: 315-322, 2004.
23. Gozes I., Fridkin M.,. Hill J.M, Brenneman D.E.: Pharmaceutical VIP: prospects and problems. Curr. Med. Chem. 6: 1019-1034, 1999.
24. Gozes I., Alcalay R., Giladi E. et al.: NAP: a neuroprotective peptide. J. Mol. Neurosci. 19: 175-178, 2002.
25. Gozes I., Steingart R.A., Spier A.D.: NAP mechanisms of neuroprotection. J. Mol. Neurosci. 24: 67-72, 2004.
26. Gressens P., Marret S., Bodenant C., Schwendimann L., Evrard P.: Activity-dependent neurotrophic factor-14 requires protein kinase C and mitogen-associated protein kinase kinase activation to protect the developing mouse brain against excitotoxicity. J. Mol. Neurosci. 13: 199-210, 1999.
27. Guo Q., Sebastian L., Sopher B.L. et al.: Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl. Acad. Sci. USA 96: 4125-4130, 1999.
28. Guo Z.H., Mattson M.P.: Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb. Cortex 10: 50-57, 2000.
29. Hashimoto Y., Ito Y., Niikura T. et al.: Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein. Biochem. Biophys. Res. Commun. 283: 460-468, 2001.
30. Hirouchi M.: Current status and perspectives on the development of therapeutic agents for Alzheimer's disease. (Article in Japanese) Nippon Yakurigaku Zasshi. 123: 421-427, 2004.
31. Ioudina M., Uemura E.: A three amino acid peptide, Gly-Pro-Arg, protects and rescues cell death induced by amyloid beta-peptide. Exp. Neurol. 184: 923-929, 2004.
32. Jaarsma D., Veenma-van der Duin L., Korf J.: N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. J. Neurol. Sci. 127: 230-233, 1994.
33. Jhamandas J.H., Harris K.H., MacTavish D., Jassar B.S.: Novel excitatory actions of galanin on rat cholinergic basal forebrain neurons: implications for its role in Alzheimer's disease. J. Neurophysiol. 87: 696-704, 2002.
34. Krejčová G., Patočka, J. Slaninová J.: Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J. Pept. Sci. 10: 636-639, 2004.
35. Lin K.F., Chang R.C., Suen K.C., So K.F., Hugon J.: Modulation of calcium/calmodulin kinase-II provides partial neuroprotection against beta-amyloid peptide toxicity. Eur. J. Neurosci 19: 2047-2055, 2004.
36. Mamiya T., Ukai M.: [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br. J. Pharmacol. 134: 1597-1599, 2001.
37. Mileusnic R., Lancashire C.L., Rose S.P.: The peptide sequence Arg-Glu-Arg, present in the amyloid precursor protein, protects against memory loss caused by A beta and acts as a cognitive enhancer. Eur. J. Neurosci. 19: 1933-1938, 2004.
38. Nieoullon A.: Alzheimer's disease: neurobiological advances supporting proposals for new therapeutical approaches. J. Appl. Biomed. 2: 123-130, 2004.
39. Niikura T., Yamada M., Chiba T. S. et al.: Characterization of V642I-AbetaPP-induced cytotoxicity in primary neurons. J. Neurosci. Res. 77: 54-62, 2004.
40. Orlando L.R., Luthi-Carter R., Standaert D.G. et al.: N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neurosci. Lett. 236: 91-94, 1997.
41. Passani L.A., Vonsattel J.P., Carter R.E., Coyle J.T.: N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. Mol. Chem. Neuropathol. 31: 97?118, 1997.
42. Patočka J., Krejčová G., Borovičková L. et al.: Humanin: Natural peptide with neuroprotective effect. Homeostasis 42: 77-78, 2003.
43. Patočka J.: Memantine and its therapeutic potential in degenerative CNS disorders (Article in Czech). Psychiatrie 6: 35-40, 2002.
44. Patočka J., Slaninová J.: Humanin - new peptide in the etiology of Alzheimer's disease (Article in Czech). Čes. Slov. Psychiat. 98: 221-222, 2002.
45. Patočka J., Slaninová J.: Neurotoxic peptides related to Alzheimer's disease. Psychiatrie 7: (Suppl. 2) 99-102, 2003.
46. Patočka J.: Some less known neuromediators. (Article in Czech). Psychiatrie 6: (Suppl. 3) 36-40, 2002.
47. Permanne B., Adessi C., Fraga S. et al.: Are betasheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J. Neural. Transm. 62 (Suppl.): 293-301, 2002.
48. Pompei P., Severini R., Pediconi D. et al.: Regulation of preprotachykinin-A gene expression in an animal model of Alzheimer's disease. J. Histochem. Cytochem. 49: 1469-1470, 2001.
49. Reilly C.E.: Beta-sheet breaker peptides reverse conformation of pathogenic prion proteins. J. Neurol. 247: 319-320, 2000.
50. Sheppard P.W., Everall I., Anderton B.H.: Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloidbeta peptide exposure: involvement of Src family protein kinases. J. Neurosci. 22: 10-20, 2002.
51. Sigalov E., Fridkin M., Brenneman D.E., Gozes I.: VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells. A model for ischemic/hypoxic injury. J. Mol. Neurosci. 15: 147-154, 2000.
52. Sisodia S.S.,.Tanzi R.E: Special Issue: Alzheimer's disease. J. Mol. Neurosci. 17: 99-270, 2001.
53. Sisodia S.S., Annaert W., Kim S.H., De Strooper B.: Gammasecretase: never more enigmatic. Trends Neurosci. 24 (Suppl): S2-S6, 2001.
54. Slaninová J., Patočka J.: Neuroprotective peptides related to Alzheimer's disease (In Czech). Psychiatrie 7: (Suppl. 2), 122-123, 2003.
55. Sokolowska P., Dejda A., Nowak J.Z: Neuroprotective role of PACAP, VIP, and PHI in the central nervous system (In Polish). Postepy Hig. Med. Dosw. 58: 416-427, 2004.
56. Steingart R.A., Solomon B., Brenneman D.E., Fridkin M., Gozes I.: VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J. Mol. Neurosci. 15: 137-145, 2000.
57. Strunecká A., Patočka J.: Aluminofluoride complexes in the etiology of Alzheimer's disease. Struct. Bonding 104: 139-180, 2003.
58. Strunecká A., Patočka J.: Lithium and Alzheimer's disease (In Czech). Psychiatrie 8: 13-16, 2004.
59. Strunecká A., Patočka J., Connet P.: Fluorine in medicine. J. Appl. Biomed. 2: 141-150, 2004.
60. Thomas A.G., Olkowski J.L., Slusher B.S.: Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation. Eur. J. Pharmacol. 426: 35-38, 2001.
61. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., Youdim M.B.: Neuroprotection via prosurvival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 18: 1471-1473, 2004.
62. White D.M., Walker S., Brenneman D.E., Gozes I.: CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Res. 868: 31-38, 2000.
63. Williamson R,. Scales T., Clark B.R. et al.: Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J. Immunol. 172: 7078-7085, 2004.
64. Xie J., Guo Q.: AATF protects neural cells against oxidative damage induced by amyloid betapeptide. Neurobiol. Dis. 16:150-157, 2004.
65. Zamostiano R.,.Pinhasov A., Gelber E. et al.: Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem. 276: 708-714, 2001.
66. Zamostiano R., Pinhasov A., Bassan M. et al.: A femtomolar-acting neuroprotective peptide induces intracellular increases in heat shock protein 60: a potential neuroprotective mechanism. Neurosci. Lett. 264: 9-12, 1999.
67. Zhu X., Wang Y., Ogawa O., et al.: Neuroprotective properties of Bcl-w in Alzheimer disease. J. Neurochem. 89: 1233-1240, 2004.